Structure Therapeutics Inc.
GPCR | NASDAQ
$36.81
+$1.81 (+5.17%)
At close: Sep 21, 2026, 4:00 PM ET
$37.48
+$0.67 (+1.82%)
Pre-market:
Sep 22, 2026, 8:11 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 3.9M | n/a | n/a | n/a | n/a | 20.03K |
Gross Profit | -3.9M | n/a | n/a | n/a | n/a | -20.03K |
Operating Income | -287.57M | -158.23M | -102.78M | -52.56M | -37.7M | -15.93M |
Interest Income | 35.97M | 36.03M | 13.38M | 1.26M | 122 | 168.29K |
Pretax Income | -140.69M | -122.22M | -89.38M | -51.3M | -37.82M | -15.77M |
Net Income | -141.2M | -122.53M | -89.62M | -51.32M | -40.01M | -15.9M |
Selling & General & Admin | 61.55M | 49.41M | 32.67M | 16.37M | 8.59M | 3.53M |
Research & Development | 225.26M | 108.81M | 70.1M | 36.19M | 29.11M | 12.39M |
Other Expenses | -3.14M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 283.67M | 158.23M | 102.78M | 52.56M | 37.7M | 15.91M |
Interest Expense | n/a | n/a | 13.39M | n/a | 122.16K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 287.57M | 158.23M | 102.78M | 52.56M | 37.7M | 15.91M |
Income Tax Expense | 515K | 310K | 236K | 17K | 231K | 138.24K |
Shares Outstanding (Basic) | 59.2M | 52.64M | 36.73M | 36.59M | 36.59M | 36.59M |
Shares Outstanding (Diluted) | 59.2M | 52.64M | 36.73M | 36.59M | 36.59M | 36.59M |
EPS (Basic) | -2.40 | -2.34 | -2.43 | -1.44 | -1.20 | -0.45 |
EPS (Diluted) | -2.40 | -2.34 | -2.43 | -1.44 | -1.20 | -0.45 |
EBITDA | -136.79M | -121.22M | -75.7M | -51.03M | -37.62M | -15.75M |
EBIT | -140.69M | -122.22M | -75.99M | -51.3M | -37.7M | -15.77M |
Depreciation & Amortization | 3.9M | 992K | 295K | 277K | 72K | 20.03K |
Add to Watchlist
Select watchlists to add or remove GPCR